This Revolutionary Biotech Is Shrouded in Mystery. Is It a Buy?
Since the beginning of the year, shares of an under-the-radar biotech company called Dyadic International (NASDAQ: DYAI) have rallied more than 87%. Without a doubt, the company is a tough nut to crack. Wading through Dyadic's presentations reveals technical jargon such as "thermophilic fungus" and "gene expression systems" that pose a barrier for potential investors trying to understand its business.
However, beneath all the scientific language is what I believe a company that can revolutionize the biotechnology industry. Even though shares have gone up a lot over the past few months, I think Dyadic is significantly underpriced compared to its future potential. Let's take a look at why.
Image source: Getty Images.
Source Fool.com
